SCHEDULE 13G/A: Wellington Management Group Discloses 2.66% Passive Stake in Ultragenyx Pharmaceutical

Wellington Management Group LLP and its affiliates have disclosed a beneficial ownership of 2.66% in Ultragenyx Pharmaceutical Inc. common stock as of December 31, 2024, held in the ordinary course of business.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively beneficially own 2,457,543 shares of Ultragenyx Pharmaceutical Inc. common stock.
• This ownership represents 2.66% of the outstanding common stock of Ultragenyx Pharmaceutical Inc.
• The reporting persons hold shared voting power over 2,108,360 shares and shared dispositive power over 2,457,543 shares.
• The shares are held on behalf of clients of various Wellington Investment Advisers and were acquired in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• This filing is an Amendment No. 2 to a Schedule 13G, updating previous beneficial ownership disclosures.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter the company's perceived value or outlook. It is a neutral disclosure of an existing passive stake.

Positives

• The disclosure of a significant stake by a major institutional investor like Wellington Management Group could be viewed as a signal of confidence in Ultragenyx Pharmaceutical Inc.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Ultragenyx Pharmaceutical Inc.'s future performance or strategic direction.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a routine disclosure by a large asset manager regarding its passive investment in a biotechnology company. It does not provide specific insights into broader industry trends or competitive dynamics beyond indicating continued institutional interest in the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a major asset manager holds a passive stake in the company.

Next Steps

• Wellington Management Group LLP and its affiliates will file future amendments to this Schedule 13G if their beneficial ownership of Ultragenyx Pharmaceutical Inc. common stock changes significantly (e.g., crosses a 1% threshold or exceeds 10%).

Key Dates

Keywords

Ultragenyx Pharmaceutical Inc., Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing